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 Abstract 
Aims. To compare the safety and efficacy of the platinum-chromium everolimus-
eluting stent (EES) with the cobalt-chromium EES. 
Methods and Results. We performed a prospective, multicentre, single-blind non-
inferiority European study randomising patients with stable or unstable coronary 
artery disease (2:1) to treatment with the platinum-chromium EES (n=1952) or the 
control cobalt-chromium EES (n=1028). The primary endpoint was target vessel 
failure (TVF) at 12 months: a  composite of target-vessel related cardiac death, 
myocardial infarction (MI), and ischaemia-driven target-vessel revascularisation 
(TVR). Of the 2, 980 study patients, 33% presented with acute coronary syndromes, 
and 48% with multivessel disease. At 12 months, the platinum-chromium EES was 
non-inferior to the cobalt-chromium EES for the primary endpoint (86 [4.6%] patients 
vs. 32 [3.2%], absolute difference 1.4%; upper limit of the one-sided 95% CI: 2.57%; 
non-inferiority P = 0.012); there were no significant differences in the rates of  cardiac 
death (1.1% vs. 1.0%, P=0.78), MI (1.6% vs. 0.8%, P=0.09), or ischaemia-driven 
TLR (2.0% vs. 1.6%, P=0.49). The rates of ARC definite or probable stent thrombosis 
were comparably low among platinum-chromium and cobalt-chromium EES patients 
(0.8% vs. 0.5% respectively, P=0.44). 
Conclusions. The platinum-chromium EES is a safe and effective alternative to the 
cobalt-chromium EES in routine clinical practice  
 
Keywords: Percutaneous coronary intervention, Coronary artery disease, Drug-
eluting stent,  Myocardial infarction,  Stent thrombosis 
Condensed Abstract 
To compare the safety and efficacy of the platinum-chromium everolimus-
eluting stent (EES) with the cobalt-chromium EES, we performed a prospective 
single-blind non-inferiority study in 48 European centres. Patients with stable or 
unstable coronary artery disease were randomised (2:1) to treatment with the 
platinum-chromium EES (PROMUS Element; n=1952) or the control cobalt-
chromium (XIENCE Prime; n=1028) EES. At 12 months, the platinum-chromium 
EES was non-inferior to the cobalt-chromium EES for target vessel failure 
(4.6%vs.3.2%; absolute difference 1.4%; upper limit of one-sided 95% confidence 
interval: 2.57%; non-inferiority P=0.012). The platinum-chromium EES is a safe and 
effective alternative to the cobalt-chromium EES in routine clinical practice. 
  
Introduction 
Ever improving coronary stent technology has yielded improved clinical 
outcomes for patients undergoing percutaneous coronary intervention (PCI). In 
particular, the cobalt-chromium everolimus-eluting stents (EES) (PROMUS, Boston 
Scientific, Marlborough, Massachusetts, USA or XIENCE V, Abbott Vascular, Santa 
Clara, California, USA) have demonstrated a reduced incidence of stent thrombosis, 
myocardial infarction (MI), and restenosis compared to the first-generation paclitaxel-
eluting stents (PES) 1-3. More recently, a third-generation platinum-chromium EES 
(PROMUS Element, Boston Scientific, Marlborough, Massachusetts, USA) has been 
designed. This novel metal alloy and redesigned scaffold architecture aims to further 
improve the acute performance of the stent by enhancing deliverability, radial 
strength, vessel conformability, and radiopacity 4, 5. This novel platform provides the 
same antiproliferative drug and biocompatible durable polymer as its cobalt-
chromium predecessor 6, 7.  
To date, the platinum-chromium EES has demonstrated equivalent safety and 
efficacy as the cobalt-chromium EES (XIENCE V) and the cobalt-chromium 
zotarolimus-eluting stent (ZES) 8, 9. The comparison between the platinum-chromium 
EES and the cobalt-chromium EES was, however, a rigorously controlled randomised 
trial of relatively low-risk patients. Thus, there remains a paucity of evidence 
comparing these two EES platforms in real-world clinical practice where up to half of 
all patients have off-label characteristics 10, 11. An all-comers trial design, with wide-
ranging inclusion and few exclusion criteria, further improves the generalisability of 
the study results and affords the opportunity to assess the impact of low-frequency, 
clinically important differences between devices. Such studies are of particular 
relevance following the publication of recommendations from the Circulatory System 
Devices Advisory Panel of the US Food and Drug Administration 12.   
We sought to determine the safety and effectiveness of the platinum-
chromium EES in an unrestricted population undergoing PCI compared to the cobalt-
chromium EES (XIENCE Prime, Abbott Vascular, Santa Clara, California). 
 
Methods 
Study design and patients 
We performed a multicentre, non-inferiority trial in 48 centres in Europe: 
France (17 centres), Germany (5), Italy (6), Macedonia (1), the Netherlands (1), Spain 
(10), Switzerland (1), and the United Kingdom (7). 
Patients aged ≥18 years of age, undergoing PCI for stable coronary artery 
disease or acute coronary syndromes (non-ST-elevation and ST-elevation MI) were 
eligible for study inclusion if they had at least one coronary artery lesion amenable to 
stent implantation, of ≥50% diameter stenosis, in a vessel of reference diameter ≥2.25 
and ≤4.25 mm by visual estimation. Single or multiple coronary artery or saphenous 
vein graft lesions were suitable and no restrictions on lesion length or complexity 
were stipulated. Patients were not excluded on the basis of comorbid medical 
conditions, except where a concurrent illness could result in non-compliance with the 
study protocol or dual antiplatelet therapy, or could limit life expectancy to ≤1 year. 
Further exclusion criteria included: left ventricular ejection fraction ≤20%; known 
hypersensitivity or contraindication to aspirin, heparin/bivalirudin, 
clopidogrel/ticlopidine, prasugrel, platinum chromium alloy, everolimus, or contrast 
media; pregnancy; participation in another investigational drug or device study; and 
an inability to provide informed consent. The study complied with the declaration of 
Helsinki and was approved by the ethics committee of all enrolling institutions. All 
patients provided written, informed consent to trial participation.  
Randomisation was performed centrally after diagnostic coronary angiography 
using an interactive internet-based allocation service. The list of treatment allocation 
was computer generated and stratified according to the enrolling centre. Patients were 
randomly allocated on a 2:1 basis to treatment with the PROMUS Element or the 
XIENCE Prime EES. The operators were aware of the assigned study stent during the 
index PCI, but the patients and clinical staff involved in follow-up care were blinded 
to the stent allocation. Clinical follow-up by office or telephonic interview was 
scheduled at 30-days, 1 and 2 years after the index intervention. 
Procedures 
All PCI procedures were performed according to standard techniques. The 
recommended pre-treatment  was 75-325 mg of aspirin, combined with a 600 mg 
loading dose of clopidogrel (if clopidogrel naïve), or a 60 mg loading dose of 
prasugrel. Unfractionated heparin, enoxaparin, or bivalirudin were administered after 
insertion of the arterial sheath, and monitoring of the anticoagulation level was 
recommended according to local laboratory practice (e.g., activated clotting time 
≥250 seconds). The use of glycoprotein IIb/IIIa inhibitors was at the discretion of the 
treating physician. Initial balloon angioplasty of the target lesion was recommended, 
though direct stenting was permitted in the study protocol. The PROMUS Element 
EES was available in diameters of 2.25, 2.5, 2.75, 3.0, 3.5, and 4.0 mm and in lengths 
of 8, 12, 16, 20, 24, 28, 32, and 38 (>2.25 mm) mm. The XIENCE Prime EES was 
available in identical diameters and in lengths of 8, 12, 15, 18, 23, 28, 33 (>2.25 mm), 
and 38 (>2.25 mm) mm. Treatment of non-target lesions with devices other than the 
study drug-eluting stent (DES) was not permitted, however staged procedures were 
allowed for multiple lesions within 42 days of the index intervention and using the 
assigned randomised DES.  
Within 24 hours prior to the scheduled PCI, all patients had a 12-lead 
electrocardiogram (ECG), and assessment of creatinine kinase (CK), CK-MB, and 
cardiac troponin levels. These tests were repeated within 24 hours after the PCI or 
prior to hospital discharge, whichever occurred first, or in suspected cases of 
myocardial ischaemia. At hospital discharge, all patients were required to take aspirin 
75-160 mg daily indefinitely, and either clopidogrel 75 mg daily or prasugrel 10 mg 
daily for at least 6 months.  
 
Endpoints and definitions 
The prespecified primary endpoint was target vessel failure (TVF) at 12 
months following index PCI. TVF was defined as the composite of cardiac death 
related to the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel, 
or ischaemia-driven revascularisation of the target vessel (TVR). Cardiac death was 
defined as death due to: MI; arrhythmia or conduction disturbance; deaths related to 
the procedure; stroke prior to hospital discharge; and death of unknown cause. 
Periprocedural MI (≤48 hours) was defined as follows: Q-Wave MI: new pathological 
Q-waves in ≥2 leads lasting ≥0.04 seconds with postprocedure CK-MB > upper limit 
of normal (ULN) (or troponin >1 × ULN with normal baseline); Non–Q-Wave MI: de 
novo CK elevation >3.0 × ULN (or troponin >3 × ULN with normal baseline) in 
absence of CK without new Q-waves, and the presence of ECG changes indicative of 
new ischaemia (new ST-T changes or left bundle branch block [LBBB]), imaging 
evidence of new loss of viable myocardium, or new regional wall motion 
abnormality. Spontaneous MI was defined as follows: Q-Wave MI: new pathological 
Q-waves in ≥2 leads lasting ≥0.04 seconds with postprocedure CK-MB > ULN (or 
troponin >1 × ULN with normal baseline); de novo CK elevation >2.0 × ULN (or 
troponin >2 × ULN with normal baseline) without new Q-waves, and the presence of 
ECG changes indicative of new ischaemia (new ST-T changes or LBBB), imaging 
evidence of new loss of viable myocardium, or new regional wall motion 
abnormality. TLR was defined as ischaemia-driven repeat PCI to the target lesion or 
coronary artery bypass grafting (CABG) distal to the target lesion. TLR was 
considered to be ischaemia-driven if the target lesion diameter stenosis was ≥70% by 
qualitative coronary angiography (QCA) or ≥50% by QCA with supporting evidence 
of clinical or functional ischaemia.  
Prespecified secondary endpoints were adjudicated at 30 days and 1 year, and 
included: TVF; ischaemia-driven target lesion revascularisation (TLR); ischaemia-
driven target vessel revascularisation (TVR); MI (Q-wave and non-Q-wave); cardiac 
death; non-cardiac death; all-cause death or MI; all-cause death/MI/TVR; major 
adverse cardiac event (MACE) rate defined as a composite of death, MI (Q-wave or 
non-Q wave), emergent CABG, or TLR; and stent thrombosis according to the ARC 
definition of definite and probable stent thrombosis and categorised as early, late or 
very late 13. TVR was defined as TLR or ischaemia-driven revascularisation of a new 
lesion within the target vessel but excluding the target lesion itself. Non-cardiac death 
was defined as a death not due to cardiac causes as outlined above. Procedural success 
was defined as mean lesion diameter stenosis <30% in 2 near-orthogonal projections 
with TIMI 3 flow, as visually assessed by the physician, without in-hospital MI, TVR, 
or cardiac death. 
All patient data were collected using an internet-based secure electronic data 
capture system. Accuracy and completeness of the recorded data was ensured by the 
site principal investigators and were verified by monitoring visits and evaluation of 
original source documents by the contract research organisation (CERC, Massy, 
France). All angiographic data were centrally stored and adjudicated at a single 
angiographic core laboratory (CERC, Massy, France) whose staff were blinded to the 
stent allocation. A blinded independent clinical events committee reviewed and 
adjudicated all clinical endpoints and adverse events including: deaths, suspected MI, 
TLR, TVR, and stent thrombosis. An independent data monitoring committee, 
comprised of interventional cardiologists and biostatisticians, reviewed accumulating 
safety data to monitor the incidence of adjudicated and non-adjudicated events and 
other trends that could warrant modification or termination of the trial. Members of 
the data monitoring committee were unaware of stent allocation but had the authority 
to unblind if required.  
Statistics 
The PLATINUM PLUS trial was designed as a non-inferiority study, powered 
for non-inferiority of the primary endpoint at 12 months. Given the reported incidence 
of 1-year TVF in the XIENCE V arms of the SPIRIT IV and V trials 8, 14, we 
projected a 12-month TVF rate of 7% for both the PROMUS Element and the 
XIENCE Prime stents. If the upper limit of the one-sided 95% confidence interval 
(CI) of the absolute risk difference was <3%, non-inferiority would be declared. 
Based on these assumptions and a 2:1 randomization, we estimated that 1987 patients 
would be required in the PROMUS Element group and 993 in the XIENCE Prime 
group (total: 2980). These estimates included a 10% expected rate of attrition and 
yielded 80% power to detect non-inferiority at a one-sided type 1 error of 0.025. We 
used a two-group Farrington-Manning test evaluate the one-sided hypothesis of non-
inferiority in proportions 15. Between group differences were compared using the chi-
square or Fischer exact test for discrete variables and the Student t test for continuous 
variables. Kaplan-Meier plots of time-to-event variables were constructed and 
treatment groups were compared using the Log-rank test. The primary and additional 
endpoints were analysed both on an intent-to-treat and on a per-protocol basis. All 
statistical analyses were performed using SAS system software (version 8 or above, 
SAS Institute, Inc., Cary, North Carolina). 
 
Results 
The derivation of the study population is depicted in Figure 1. Between 
February 2010 and October 2012, a total of 2980 patients were randomised to receive 
the PROMUS Element (N=1952) or XIENCE Prime (N=1028) DES. The baseline 
clinical and angiographic characteristics of the study groups were well matched 
(Table 1). The mean age was 65.8±10.6 years, 77.9% were male, and 29.4% had 
diabetes mellitus. One third (33.2%) presented with coronary syndromes. The left 
main was the target vessel in 6.5% and the left anterior descending was the most 
frequently treated vessel (65.9%). Almost half of all patients (48.3%) had multiple 
target vessels with an average 1.6±0.9 target lesions per patient.  
Procedural and angiographic details are presented in Table 2. These 
characteristics were well matched between groups. The average stent length and 
diameter per target lesion were 23.93±13.87 mm and 3.00±0.47 mm, respectively. 
The mean number of stents per target lesion was 1.18±0.49 and, on average, each 
patient received 1.73±1.11 stents. Procedural success was observed in 97.6% in the 
PROMUS Element group and in 97.8% in the XIENCE Prime group (P=0.78). 
Clinical Outcomes 
As depicted in Figure 1, 30-day follow-up was available in 99.1% of the 
PROMUS Element group and in 99.7% of the XIENCE Prime group (P=0.11). The 
rates of adverse events were similar in both groups at 30 days (Table 3). In the 
intention to treat analysis, TVF occurred in 1.3% of the PROMUS Element group and 
in 0.9% of the XIENCE Prime group (P=0.27). 
At 12 months, the primary endpoint occurred in 86 (4.6%) patients with the 
PROMUS Element stent and 32 (3.2%) with the XIENCE Prime stent (Figure 2). 
Non-inferiority of the PROMUS Element stent was established, with an absolute risk 
difference of 1.4%, and the upper limit of the one-sided 95% CI at 2.57%, which was 
less than the pre-specified non-inferiority margin of <3.0% (one-sided P value for 
non-inferiority = 0.012) (Figure 3). The results were similarly robust when patients 
that did not receive the allocated stent were excluded from the analysis (per-protocol 
analysis; data not shown). 
At 12 months, we observed no significant difference in the individual rates of 
death, cardiac death, MI, and TLR between the PROMUS Element and XIENCE 
Prime stents (Table 4, Figure 4). The rates of ARC definite or probable stent 
thrombosis at 12 months were also similar between groups (0.8% vs. 0.5%, P=0.44). 
 Discussion 
The current multicentre randomised all-comers PLATINUM PLUS clinical 
trial demonstrates that the rate of TVF with the PROMUS Element EES is non-
inferior to that of the XIENCE Prime EES at 12-month follow-up. Indeed, this study 
observed excellent safety and efficacy of both EES platforms, with low rates of MI, 
stent thrombosis and ischaemia-driven TLR in a real world patient population.  
Large randomised trials have previously observed superior performance with 
EES compared to PES 1, 3, 16. The supremacy of the second-generation EES 
manifested in lower rates of TVF, TLR, MI, and stent thrombosis than the first-
generation PES. Recently published data also suggest a potential mortality advantage 
of EES over PES 17. EES have also demonstrated equivalent performance to second-
generation ZES (Resolute, Medtronic Cardiovascular, Santa Rosa, California) 18-20. 
The continued development of DES has focussed on enhancing each of the 3 
major elements of the stent platform: the stent scaffold, the polymer, and the anti-
proliferative agent. The PROMUS Element DES comprises a novel platinum-
chromium stent with modified stent architecture, and the previously tested durable 
biocompatible polymer and antiproliferative agent 8. Specifically, the design goals of 
the platinum-chromium scaffold were to improve deliverability, radial strength, vessel 
conformability, radiopacity, and side-branch accessibility, without compromising the 
safety and efficacy profile of the stent 4, 5. In this regard, animal models have 
suggested that the platinum-chromium EES yields drug-elution kinetics and drug 
tissue concentrations similar to its cobalt-chromium equivalent 21. Supporting clinical 
data comes from the PLATINUM trial 8. This prospective study randomised 1530 
patients undergoing PCI for de novo stable coronary artery disease to treatment with 
the PROMUS Element or XIENCE V EES. At 1-year, the platinum-chromium EES 
was non-inferior to its cobalt-chromium equivalent (TVF 3.4% vs. 2.9%; absolute risk 
difference 0.5%, 95% CI -1.3% to 2.3%; upper limit of one-sided 95% CI 2.13%; 
non-inferiority P = 0.001). While these data suggest clinical equipoise between the 
EES platforms, patients with acute MI, true bifurcation lesions, left main stenosis, and 
chronic total occlusions were excluded from the PLATINUM study. Consequently, 
this study does not provide insight into the majority of patients undergoing PCI in the 
real-world setting 10, 11. As such, the Circulatory System Devices Advisory panel of 
the FDA recommends that all new DES be tested in well-designed trials in off-label 
indications 12. The recently reported phenomenon of longitudinal stent deformation 
underscores the need to undertake all-comer comparative safety and effectiveness 
studies 22.   
The current randomised trial included the largest number of patients (N=2980) 
randomised to platinum-chromium or cobalt-chromium EES. One third of patients 
presented with acute MI and almost half had multivessel disease. In this all-comer 
population, the PROMUS Element EES was non-inferior to the XIENCE Prime EES 
for the composite safety and efficacy endpoint of TVF at 12 months. Acute 
procedural success (>97%) was excellent for both platforms and no significant 
differences in the individual rates of death, MI, or ischaemia-driven TLR were 
evident between the groups. Importantly, the 1-year incidence of ARC-defined 
definite or probable stent thrombosis was reassuringly low in both the platinum-
chromium (0.8%) and cobalt chromium (0.5%) EES.  
Recently, the PROMUS Element EES was compared to the cobalt-chromium-
based ZES in an investigator-initiated prospective single-blind all-comer randomised 
trial 9. Among 1811 patients, 45% presented with acute coronary syndromes. The 
primary outcome measure (TVF) occurred in 5% of EES-treated and 6% of the ZES-
treated patients (absolute risk difference 0.88%, 95% CI -1.24% to 3.01%; upper limit 
of one-sided 95% CI 2.69%; non-inferiority P = 0.006). These data, when considered 
in tandem with the current study, would appear to confirm that the platinum-
chromium EES provides similar efficacy and safety to third-generation cobalt-
chromium EES and ZES. 
Limitations 
At 12-month follow-up, the rate of TVF in the XIENCE Prime control arm 
was 3.2%, and was consequently less than the expected 7% rate used for the sample 
size calculation.  Thus, although the absolute difference in TVF at 12 months was 
small (1.4%), the current study cannot absolutely exclude small differences in event 
rates between the test stents. Extended follow-up is required to demonstrate 
equivalent longer-term outcomes.  
Conclusions 
In this large-scale all-comers prospective randomised trial, the platinum-
chromium EES demonstrated non-inferiority to the cobalt-chromium EES for TVF at 
12-months.  
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Figure 1. Derivation of the Study Population 
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Legend. Patient flow in the PLATINUM PLUS randomised trial. * Follow-up rate for 
clinical endpoint.  
 
 
 
 
 
 
Figure 2. Kaplan-Meier Curves for the Primary Endpoint at 12 Months 
 
Legend. Kaplan-Meier curves for the primary endpoint in the intention to treat 
analysis at 12 months.   
 
 
 
 
 
 
 
 
Figure 3. TVF: Primary Endpoint at 12 Months (ITT). 
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Legend. The primary endpoint of the study was target vessel failure (TVF) at 12 
months in the intention-to-treat analysis. The plot demonstrates the difference in TVF 
between the PROMUS Element and XIENCE Prime stents at 12 months, and the 
upper bound of the one-sided 95% confidence interval (blue line). 
 
 
 
 
 
 
  
 
Figure 4. Kaplan-Meier Curves for All Cause Death, Myocardial Infarction, and 
Target Lesion Revascularisation at 12 Months ( ITT) 
 Legend. Kaplan-Meier curves for (A) all-cause death, (B) myocardial infarction, and 
(C) target lesion revascularisation in the intention to treat analysis at 12 months.   
Tables. 
Table 1. Baseline Clinical Characteristics 
 PROMUS Element 
(N=1952 
XIENCE Prime 
(N=1028) 
P  
Age, years 65.7 ± 10.5 66.1 ± 10.7 0.29 
Male sex 1515 (77.7) 806 (78.4) 0.64 
Hypertension 1282 (68.0) 684 (68.6) 0.74 
Hypercholesterolaemia 1195 (63.4) 620 (62.2) 0.52 
Diabetes mellitus 568 (29.1) 280 (27.2) 0.30 
   Insulin treated  147 (7.8) 71 (7.1) 0.51 
Current smoker 414 (22.0) 208 (20.9) 0.49 
Family history of IHD 657 (34.9) 349 (35.0) 0.94 
Prior myocardial infarction 422 (21.7) 250 (24.3)  0.10 
Indication    
   Stable angina 879 (45.2) 458 (44.6) 0.75 
   Silent ischaemia 207 (10.7) 117 (11.4)  0.54 
   Acute coronary syndrome  645 (33.2) 340 (33.1) 0.97 
Location of target lesions    
   Left main 123 (6.3) 69 (6.7) 0.68 
   Left anterior descending 1261 (64.9) 697 (67.9) 0.10 
   Left circumflex 913 (47.0) 439 (42.8) 0.028 
   Right 992 (51.0) 506 (49.3) 0.36 
   Multivessel disease 949 (48.8) 486 (47.3) 0.44 
Number of target lesions 1.6±0.9 1.6±0.8 0.96 
   1 1194 (61.8) 630 (61.8) 0.98 
   2 496 (25.7) 266 (26.1) 0.81 
   3 168 (8.7) 86 (8.4) 0.81 
   4+ 74 (3.8) 38 (3.7) 0.89 
Target lesion measures    
   Reference vessel diameter, mm 2.99±0.5 2.98±0.5 0.90 
   Diameter stenosis, % 83.3±11.6 82.8±12.2 0.32 
   Lesion length, mm 19.4±11.9 19.2±10.9 0.75 
 
Legend. Values are mean ± SD or number (%). IHD = ischaemic heart disease. 
 
 
 
  
Table 2. Procedural Characteristics 
 PROMUS Element 
(N=1952 
XIENCE Prime 
(N=1028) 
P 
Transradial access 62.0% 62.2% 0.91 
Stents/patient 1.72±1.09 1.76±1.14 0.67 
   1 1019 (52.2) 533 (51.9) 0.84 
   2 533 (27.3) 274 (26.6) 0.70 
   3+ 354 (18.1) 198 (19.2) 0.46 
Stents/target lesion 1.17±0.48 1.2±0.51 0.013 
Mean stent diameter, mm 2.99± 0.47  3.00±0.47  0.87 
Total stent length/lesion, mm 23.90±13.83 23.98±13.95 0.30 
Total stent length/lesion length ratio, 
mm 
1.32±0.66 1.32±0.74 0.59 
Total stent length/patient, mm 35.9 ± 24.8 35.8 ± 25.2 0.51 
Maximal stent balloon pressure, atm 14.86±2.86 14.70±3.12 0.03 
Lesion postdilatation 1205 (41.2) 653 (42.4) 0.43 
 
Legend. Values are mean ± SD or number (%). 
 
 
 
 Table 3. 30-day Clinical Outcomes 
 PROMUS Element 
(N=1935) 
XIENCE Prime 
(N=1025) 
P 
TVF  
26 (1.3) 9 (0.9) 0.27 
All death 11 (0.6)  5 (0.5)  0.78 
   Cardiac death 10 (0.5) 5 (0.5) 0.92 
     Related to target vessel 10 (0.5) 4 (0.4) 0.78 
     Not related to target vessel 0 (0.0) 1 (0.1) 0.35 
   Non-cardiac death 1 (0.1) 0 (0.0) 0.99 
MI 13 (0.7) 5 (0.5)  0.54 
   Related to target vessel 13 (0.7) 4 (0.4) 0.34 
   Not related to target vessel 0 (0.0) 1 (0.1) 0.35 
   Q-wave MI 4 (0.2)  0 (0.0) 0.31 
   Non-Q wave MI 9 (0.5) 5 (0.5) 0.99 
TVR 7 (0.4) 2 (0.2)  0.73 
   TLR 6 (0.3) 1 (0.1) 0.43 
   Non-TLR 1 (0.1) 1 (0.1) 0.99 
TLF 25 (1.3) 8 (0.8) 0.21 
Cardiac death/MI 22 (1.1) 10 (1.0) 0.69 
Death/MI/TVR 27 (1.4) 11 (1.1) 0.46 
MACE 26 (1.3) 10 (1.0) 0.39 
ARC stent thrombosis: definite or probable* 11 (0.6)  3 (0.3) 0.40 
   Definite 4 (0.2) 1 (0.1) 0.67 
   Probable 7 (0.4) 2 (0.2) 0.73 
   Possible 1 (0.1) 0 (0.0) 0.99 
 
Legend. Values are number (%). TVF = target vessel failure; MI = myocardial 
infarction; TVR = target vessel revascularisation; TLR = target lesion 
revascularisation; PCI = percutaneous coronary intervention; CABG = coronary 
artery bypass grafting; MACE = major adverse cardiovascular events. * Academic 
Research Consortium definition 13. 
 
 
 
 
 
 
 
  
Table 4. 12-Month Clinical Outcomes 
 PROMUS Element 
(N=1862) 
XIENCE Prime 
(N=987) 
P 
TVF 
86 (4.6) 32 (3.2) 0.08 
All death 33 (1.8)  15 (1.5)  0.62 
   Cardiac death 21 (1.1) 10 (1.0) 0.78 
     Related to target vessel 17 (0.9) 9 (0.9) 0.99 
     Not related to target vessel 4 (0.2) 1 (0.1) 0.66 
   Non-cardiac death 12 (0.6) 5 (0.5) 0.65 
MI 29 (1.6) 8 (0.8)  0.09 
   Related to target vessel 24 (1.3) 5 (0.5) 0.05 
   Not related to target vessel 6 (0.3) 3 (0.3) 0.99 
   Q-wave MI 4 (0.2)  3 (0.3) 0.70 
   Non-Q wave MI 25 (1.3) 6 (0.6) 0.07 
TVR 59 (3.2) 20 (3.0)  0.08 
   TLR 37 (2.0) 16 (1.6) 0.49 
   Non-TLR 25 (1.3) 7 (0.7) 0.13 
Cardiac death/MI 49 (1.6) 18 (1.8) 0.18 
Death/MI/TVR 106 (5.7) 41 (4.2) 0.08 
MACE 87 (4.7) 38 (3.9) 0.31 
ARC stent thrombosis: definite or probable* 14 (0.8)  5 (0.5) 0.44 
   Definite 6 (0.3) 3 (0.3) 0.99 
   Probable 8 (0.4) 2 (0.2) 0.51 
   Possible 1 (0.1) 2 (0.2) 0.28 
 
 
Legend. Values are number (%). * Academic Research Consortium definition 13. 
